

CITATION REPORT

List of articles citing

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden

DOI: 10.1371/journal.pone.0228288
PLoS ONE, 2020, 15, e0228288.

Source: <https://exaly.com/paper-pdf/77424312/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice. <i>Clinical Therapeutics</i> , 2020 , 42, 1682-1698.e7	3.5	6
8	Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 381-393	2.2	0
7	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 461-464	3.5	1
6	Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. <i>Journal of Immunotherapy</i> , 2021 , 44, 198-203	5	0
5	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 639745	5.3	2
4	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021 , 23, 119	6.3	0
3	Prognostication Based on Texture Analysis of Baseline F Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Nonsmall-Cell Lung Carcinoma Patients Who Underwent Platinum-Based Chemotherapy as First-Line Treatment. <i>Indian Journal of Nuclear Medicine</i> , 2021 , 36, 252-260	0.4	1
2	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102031	14.4	37
1	Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.		0